CYCLERION THERAPEUTICS, INC. Revenue from Contract with Customer, Excluding Assessed Tax
CYCLERION THERAPEUTICS, INC. (CYCN) reported Revenue from Contract with Customer, Excluding Assessed Tax of $2.30 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2021-02-25
- CYCLERION THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-12-31 was $133.00K, a 91.02% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-09-30 was $400.00K, a 71.39% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-06-30 was $749.00K, a 53.99% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-03-31 was $1.01M.
- CYCLERION THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $2.30M, a 49.06% decline from fiscal 2019.
- CYCLERION THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $4.51M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | $133.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $533.00K derived: sum of 2 quarters · filed 2021-02-25 | $1.28M derived: sum of 3 quarters · filed 2021-02-25 | $2.30M 10-K · filed 2021-02-25 |
| 2020-09-30 | $400.00K 10-Q · filed 2020-11-05 | $1.15M derived: sum of 2 quarters · filed 2020-11-05 | $2.16M 10-Q · filed 2020-11-05 | $3.64M derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-06-30 | $749.00K 10-Q · filed 2020-08-03 | $1.76M 10-Q · filed 2020-08-03 | $3.24M derived: sum of 3 quarters · filed 2021-02-25 | $4.64M derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-03-31 | $1.01M 10-Q · filed 2020-05-04 | $2.50M derived: sum of 2 quarters · filed 2021-02-25 | $3.89M derived: sum of 3 quarters · filed 2021-02-25 | $5.52M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.88M derived: sum of 2 quarters · filed 2021-02-25 | $4.51M derived: sum of 3 quarters · filed 2021-02-25 | $4.51M 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.40M 10-Q · filed 2020-11-05 | $3.03M derived: sum of 2 quarters · filed 2020-11-05 | $3.03M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.63M 10-Q · filed 2020-08-03 | $1.63M 10-Q · filed 2020-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |